Sign in or create an account to add this stock to your watchlist.
About OXiGENE (OTCMKTS:MATN)
Mateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors. The company also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MATN
CUSIPN/A
Phone650-635-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio0.26
Quick Ratio0.26
Price-To-Earnings
Trailing P/E Ratio-0.40
Forward P/E Ratio-1.15
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.03) per share
Price / Book-6.87
Profitability
EPS (Most Recent Fiscal Year)($0.52)
Net Income$-13,810,000.00
Net MarginsN/A
Return on Equity-802.11%
Return on Assets-384.06%
Miscellaneous
Employees5
Outstanding Shares41,420,000
OXiGENE (OTCMKTS:MATN) Frequently Asked Questions
What is OXiGENE's stock symbol?
OXiGENE trades on the OTCMKTS under the ticker symbol "MATN."
How were OXiGENE's earnings last quarter?
OXiGENE, Inc. (OTCMKTS:MATN) released its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. View OXiGENE's Earnings History.
What price target have analysts set for MATN?
2 brokerages have issued 1-year price targets for OXiGENE's stock. Their predictions range from $1.00 to $1.00. On average, they expect OXiGENE's stock price to reach $1.00 in the next twelve months. View Analyst Ratings for OXiGENE.
What are Wall Street analysts saying about OXiGENE stock?
Here are some recent quotes from research analysts about OXiGENE stock:
- 1. According to Zacks Investment Research, "Mateon Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents for the treatment of cancer. Its product pipeline consists of VDAs-CA4P and OXi4503, which are in preclinical trail stage. Mateon Therapeutics, Inc., formerly known as OXiGENE, Inc., is based in SOUTH SAN FRANCISCO, United States. " (4/21/2018)
- 2. Maxim Group analysts commented, "Mateon announced that the P1b/2 trial (investigator-sponsored) evaluating the company’s lead combretastatin, CA4P, in combination with pazopanib (tyrosine kinase inhibitor, TKI) in recurrent ovarian cancer has been stopped (for now) as serious adverse events (SAEs) have emerged." (6/7/2017)
Who are some of OXiGENE's key competitors?
Some companies that are related to OXiGENE include Oncobiologics (ONS), aTyr Pharma (LIFE), Neuralstem (CUR), Genetic Technologies (GENE), Titan Pharmaceuticals (TTNP), TrovaGene (TROV), Windtree Therapeutics (WINT), Mymetics (MYMX), Enzon Pharmaceuticals (ENZN), Gene Biotherapeutics (CRXM), Vitro Diagnostics (VODG) and Omni Bio Pharmaceutical (OMBP).
Who are OXiGENE's key executives?
OXiGENE's management team includes the folowing people:
- Dr. William D. Schwieterman M.D., Chairman, Chief Exec. Officer and Pres (Age 60)
- Mr. Matthew M. Loar, Chief Financial Officer (Age 55)
- Dr. David John Chaplin B.Sc, M.Sc, Ph.D., Chief Scientific Officer and Director (Age 62)
- Ms. Shari Annes, Exec. Officer of Investor Relations
- Dr. Yuval Binur Ph.D., Exec. VP of Financial
Has OXiGENE been receiving favorable news coverage?
News stories about MATN stock have trended positive recently, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OXiGENE earned a news impact score of 0.29 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.04 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of OXiGENE?
Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OXiGENE's stock price today?
One share of MATN stock can currently be purchased for approximately $0.2061.
How big of a company is OXiGENE?
OXiGENE has a market capitalization of $9.10 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. OXiGENE employs 5 workers across the globe.
How can I contact OXiGENE?
OXiGENE's mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]
MarketBeat Community Rating for OXiGENE (MATN)
MarketBeat's community ratings are surveys of what our community members think about OXiGENE and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.
OXiGENE (OTCMKTS:MATN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for OXiGENE in the last 12 months. Their average twelve-month price target is $1.00, suggesting that the stock has a possible upside of 385.20%. The high price target for MATN is $1.00 and the low price target for MATN is $1.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.00 | $1.50 | $1.75 | $1.75 |
| Price Target Upside: | 385.20% upside | 528.14% upside | 651.07% upside | 651.07% upside |
OXiGENE (OTCMKTS:MATN) Consensus Price Target History
OXiGENE (OTCMKTS:MATN) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
OXiGENE (OTCMKTS:MATN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OXiGENE (OTCMKTS MATN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.60%
OXiGENE (OTCMKTS MATN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/16/2016 | Donald Rogers Reynolds | Director | Buy | 30,000 | $0.35 | $10,500.00 | 12,700 |  |
| 6/28/2013 | Peter Langecker | CEO | Buy | 3,000 | $2.75 | $8,250.00 | | |
| 6/25/2013 | Peter Langecker | CEO | Buy | 2,000 | $2.79 | $5,580.00 | | |
(Data available from 1/1/2013 forward)
OXiGENE (OTCMKTS MATN) News Headlines
| Source: |
|
OXiGENE (OTCMKTS:MATN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OXiGENE (OTCMKTS:MATN) Income Statement, Balance Sheet and Cash Flow Statement
OXiGENE (OTCMKTS MATN) Stock Chart for Thursday, May, 24, 2018
Loading chart…
